<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 11, 2001
VION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
<TABLE>
<S> <C> <C>
Delaware 0-26534 13-3671221
------------------------------ --------------- --------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
4 Science Park, New Haven, CT 06511
---------------------------------------- -------
(Address of Principal Executive Offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code: (203) 498-4210
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS
In a press release dated January 11, 2001, Vion Pharmaceuticals Inc.
(the "Company") presented the status of Phase I trials of its leading anticancer
agents, TAPET and Triapine.
The Company also announced that a copy of the corporate slide
presentation, highlighting the affairs of the Company, which shall be presented
at the Annual J.P. Morgan H&Q Conference held on January 11, 2001, will be
available via live, audio web-cast at www.jpmhq.com/events, at 8:30 a.m. Pacific
Time and can also be found on the Company's website (www.vionpharm.com), at
approximately 8:45 a.m. Pacific Time on January 11, 2001.
A copy of the press release is attached as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) EXHIBITS.
Exhibit 99.1 Press release dated January 11, 2001 reporting
the status of Phase I trials of the Company's leading
anticancer agents, TAPET and Triapine.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VION PHARMACEUTICALS, INC.
Date: January 11, 2001 By: /s/ Alan Kessman
------------------
Name: Alan Kessman
Title: President and Chief Executive Officer
<PAGE>
EXHIBIT INDEX
99.1 Press release dated January 11, 2001 reporting the status of
Phase I trials of the Company's leading anticancer agents,
TAPET and Triapine.
STATEMENT OF DIFFERENCES
The registered trademark symbol shall be expressed as.......................'r'
